Laine A, Davril M, Rabaud M, Vercaigne-Marko D, Hayem A
Eur J Biochem. 1985 Sep 2;151(2):327-31. doi: 10.1111/j.1432-1033.1985.tb09104.x.
Incubation of human serum alpha 1-antichymotrypsin with human pancreatic elastase 2 or porcine pancreatic elastase results in the complete inhibition of each enzyme as determined by spectrophotometric assays. alpha 1-Antichymotrypsin reacts much more rapidly with the human than with the porcine enzyme. The inhibitor: enzyme molar ratio, required to obtain full inhibition of enzymatic activity, is equal to 1.25/1 when alpha 1-antichymotrypsin reacts with human pancreatic elastase 2 while it is markedly higher with porcine pancreatic elastase (5.5/1). Patterns obtained by SDS/polyacrylamide gel electrophoresis of the reaction products show the formation with both enzymes of an equimolar complex (Mr near 77 000) and the release of a fragment migrating as a peptide of Mr near 5000. Moreover a free proteolytically modified form of alpha 1-antichymotrypsin, electrophoretically identical with that obtained in the reaction with cathepsin G or bovine chymotrypsin, is produced in the reaction with each elastase but in a much greater amount when alpha 1-antichymotrypsin reacts with porcine elastase than with human elastase. As a consequence of our findings, the specificity of alpha 1-antichymotrypsin, so far limited to the inhibition of chymotrypsin-like enzymes from pancreas and leukocyte origin, has to be extended to the two pancreatic elastases investigated in this work. A contribution of alpha 1-antichymotrypsin to the regulatory balance between plasma inhibitors and human pancreatic elastase 2 in pancreatic diseases is suggested.
通过分光光度法测定,人血清α1 -抗胰凝乳蛋白酶与人胰腺弹性蛋白酶2或猪胰腺弹性蛋白酶温育会导致每种酶完全被抑制。α1 -抗胰凝乳蛋白酶与人源酶的反应比与猪源酶的反应快得多。当α1 -抗胰凝乳蛋白酶与人胰腺弹性蛋白酶2反应时,获得酶活性完全抑制所需的抑制剂与酶的摩尔比等于1.25/1,而与猪胰腺弹性蛋白酶反应时该比值明显更高(5.5/1)。反应产物的SDS/聚丙烯酰胺凝胶电泳图谱显示,与两种酶都形成了等摩尔复合物(Mr接近77000),并释放出一个迁移率与Mr接近5000的肽段的片段。此外,在与每种弹性蛋白酶的反应中都会产生一种游离的经蛋白水解修饰的α1 -抗胰凝乳蛋白酶形式,其电泳图谱与在与组织蛋白酶G或牛胰凝乳蛋白酶反应中获得的相同,但当α1 -抗胰凝乳蛋白酶与猪弹性蛋白酶反应时产生的量比与人弹性蛋白酶反应时多得多。基于我们的研究结果,α1 -抗胰凝乳蛋白酶的特异性,迄今为止仅限于抑制来自胰腺和白细胞来源的类胰凝乳蛋白酶,必须扩展到本研究中所研究的两种胰腺弹性蛋白酶。这表明α1 -抗胰凝乳蛋白酶在胰腺疾病中对血浆抑制剂与人类胰腺弹性蛋白酶2之间的调节平衡有贡献。